TherOx
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, TherOx sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
TherOx: 6 sponsored US clinical trials, 2 recruiting.
TherOx sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is AMI, with 1 trials.
Upper-quartile sponsor footprint
TherOx sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
SuperSaturated Oxygen Comprehensive Observational Registry
NCT06438315
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
NCT04743245
A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System
NCT05156996
Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)
NCT02603835
Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
NCT01630707
Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)
NCT00175058
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where TherOx enrollment is open (later-stage tilt)
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: AMI (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
TherOx: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
TherOx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this TherOx page
6 registered trials is a research-attention snapshot, not an endorsement of TherOx or any single study.
- 2 of TherOx's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- AMI is the condition TherOx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See AMI trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
TherOx pipeline card: 6 registered trials from official public datasets.Report a data error.